Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Nanomedicine (Lond). 2013 Feb 28;8(12):10.2217/nnm.12.200. doi: 10.2217/nnm.12.200

Figure 5. In vivo suppression by tetraiodothyroacetic acid versus tetraiodothyroacetic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles in drug-resistant breast cancer orthotopic tumor mouse model.

Figure 5

Treatment with tetrac and T-PLGA-NPs (1 mg/kg bodyweight) was started on day 8, after orthotopically implanting doxorubicin-resistant MCF7 cells in female BALBc nude mice, and continued daily. (A) Effect of tetrac and T-PLGA-NP treatment on doxorubicin-resistant MCF7 tumor volume over time, up to 16 days. Data represent mean tumor volume (mm3) ± standard deviation; n = 8 per group. (B) Effect on tumor weight at day 16 after the treatments (end of study).

tetrac: Tetraiodothyroacetic acid; T-PLGA-NPs: Tetraiodothyroacetic acid conjugated to poly(lactic-co-glycolic acid) nanoparticles.